US PTAB IP Litigation
5,620 annotated decisions
Page 118 of 235 · 5,620 total
patent terminated or settled · Nov 29, 2024
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
· IPR2025-00162
Samsung and SiOnyx reached a settlement that terminated the inter partes review of U.S. Patent 10,224,359 before the trial was instituted. The Board ordered the settlement and related license agreement to be kept confidential.
patent terminated or settled · Nov 29, 2024
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
· IPR2025-00162
Samsung and SiOnyx have settled their dispute over U.S. Patent 10,224,359 and jointly moved to terminate the pending inter partes review, requesting the settlement be kept confidential.
patent · Nov 29, 2024
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
· IPR2025-00165
Samsung has filed an IPR petition seeking cancellation of all 36 claims of SiOnyx’s ’599 image‑sensor patent, asserting that each claim is obvious over a suite of prior‑art references. The petition also argues that discretionary denial is inappropriate given the lack of prior petitions and a stayed ITC case.
patent · Nov 29, 2024
Samsung Electronics Co., Ltd. et al. v.SiOnyx, LLC
· IPR2025-00162
Samsung has filed an IPR petition to cancel 79 claims of SiOnyx’s 10,224,359 image‑sensor patent, asserting that the claims are anticipated or obvious over Iida and other prior art. The petition also argues that a discretionary denial would be improper.
patent instituted · Nov 29, 2024
Micron Technology, Inc. et al. v.Yangtze Memory Technologies Company, Ltd.
· IPR2025-00228
Micron Technology successfully secured the institution of an IPR against Yangtze Memory Technologies' patent 11,101,276 B2. The Board found a reasonable likelihood that Micron can prove obviousness over prior art references like Kim and Fang.
patent · Nov 27, 2024
Precision Cancer Technologies Inc. v.Oncoustics Inc.
· IPR2025-00242
Precision Cancer Technologies has requested a PTAB Director Review of IPR2025-00242. The Patent Owner, Oncoustics, is limited to a brief response within five days, with no new evidence allowed.
patent denied · Nov 27, 2024
Precision Cancer Technologies Inc. v.Oncoustics Inc.
· IPR2025-00242
Oncoustics successfully defended the Board’s decision to deny institution of an IPR filed by Precision Cancer Technologies. The patent owner showed the petitioner failed to prove the primary reference disclosed a single static set of raw RF ultrasound data, and the petitioner’s new arguments were untimely.
patent · Nov 27, 2024
Cellco Partnership d/b/a Verizon Wireless et al. v.Pegasus Wireless Innovation LLC
· IPR2025-00138
Verizon and other carriers filed a petition for Director Review after the PTAB denied institution of an IPR against KT Corp.’s wireless patent. They claim the Board misapplied Fintiv factors and retroactively changed guidance, violating due process. The petition seeks reversal of the discretionary denial.
patent · Nov 27, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00114
Abbott Laboratories submits a response urging the PTAB Director to deny Miracor Medical’s request for review of the institution decision in IPR2025-00114. The petitioner argues the Board’s findings on particularity, claim construction, word count, and Fintiv factors were proper and that the request would be inefficient.
patent denied · Nov 27, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00116
The PTAB denied Abbott Laboratories' request for Director Review of the institution decisions in three IPRs, including IPR2025-00116 covering Miracor Medical's patent 11,754,077 B1. The institution decisions remain in effect.
patent · Nov 27, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00114
Abbott Laboratories’ petition to institute an IPR against Miracor Medical’s heart‑pump patent is challenged by Miracor, which argues the petition lacks particularity, violates claim‑construction rules, and circumvents word‑count limits, seeking discretionary denial under § 314(a).
patent · Nov 27, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00116
Abbott Laboratories has filed an IPR petition seeking cancellation of 18 claims of Miracor’s LVAD patent (US 11,754,077). The petition alleges obviousness over four prior‑art references and argues the petition is not barred. The Board’s decision on institution is pending.
patent · Nov 27, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00114
Abbott Laboratories has filed an IPR petition challenging Miracor Medical’s U.S. Patent 11,572,879 covering an implantable LVAD. The petition asserts that four prior‑art references render all asserted claims obvious under 35 U.S.C. §103. The case is currently pending before the PTAB.
patent · Nov 27, 2024
Cellco Partnership d/b/a Verizon Wireless et al. v.Pegasus Wireless Innovation LLC
· IPR2025-00138
Cellco Partnership and other major carriers petition the PTAB to institute an IPR against Pegasus Wireless Innovation's ’931 patent covering MTC uplink control channel resource allocation, asserting obviousness over standard 3GPP references. The petition argues the Board should not deny institution under §325(d) or §314(a).
patent denied · Nov 27, 2024
Precision Cancer Technologies Inc. v.Oncoustics Inc.
· IPR2025-00242
Precision Cancer Technologies Inc.'s IPR challenge against Oncoustics Inc. was denied by the PTAB, failing to meet the reasonable likelihood of prevailing standard. The Board found Petitioner failed to sufficiently demonstrate that prior art processed a 'single static set' of raw RF ultrasound data.
patent denied · Nov 27, 2024
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
· IPR2025-00237
Curio Bioscience, Inc.'s IPR challenge against Prognosys and 10X Genomics was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing on grounds of obviousness (over Cantor/Armani) and anticipation (by Frisen).
patent instituted · Nov 27, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00116
Abbott Laboratories challenged MIRACOR MEDICAL SA's heart assist pump patent (11754077) on grounds of obviousness over Wampler and Bourque. The PTAB instituted the IPR, affirming plain meanings for key terms like 'magneto coupling,' while finding Petitioner's rationale persuasive regarding combination art.
patent instituted · Nov 27, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00114
Abbott Laboratories successfully petitioned to institute IPR against MIRACOR MEDICAL SA's heart assist pump patent (US 11,572,879 B2). The Board adopted broader claim constructions for key terms like 'magneto coupling,' leading to institution on all 15 challenged claims.
patent · Nov 26, 2024
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
· PGR2025-00004
Halozyme seeks Director Review to overturn the PTAB’s institution of a post‑grant review against its hyaluronidase patent, arguing filing‑date errors, improper claim construction, and Fintiv factors favoring denial.
patent · Nov 26, 2024
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
· PGR2025-00004
Merck has filed a petition to invalidate Halozyme’s ’298 patent covering modified PH20 polypeptides, arguing the claims lack written description and enablement. The reply attacks Halozyme’s reliance on functional language and disclaimed dependent claims.
patent instituted · Nov 26, 2024
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
· PGR2025-00004
Merck challenges Halozyme’s request for Director review after the PTAB instituted a post‑grant review of U.S. Patent 12,018,298 covering modified PH20 polypeptides. Merck argues the eligibility and claim‑construction issues are meritless and that the Fintiv factors favor institution.
patent · Nov 26, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00115
Abbott Laboratories submits an authorized response urging the PTAB Director to deny Miracor Medical’s request for review of the institution decision, arguing the Board already resolved all substantive issues and that new Fintiv arguments are barred.
patent denied · Nov 26, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00115
The PTAB denied Director Review requests for three IPR institution decisions, including IPR2025-00115 concerning patent 11,674,517 owned by Miracor Medical and challenged by Abbott Laboratories. The institution decisions therefore remain in effect.
patent · Nov 26, 2024
Abbott Laboratories et al. v.MIRACOR MEDICAL SA
· IPR2025-00115
Miracor Medical seeks Director Review to deny Abbott’s institution of IPR 2025‑00115, arguing procedural deficiencies, lack of particularity, improper claim constructions, and word‑count violations. The Board had previously instituted the IPR on numerous cardiac‑pump claims.
